SRR5088814
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- CHOLESTEROL_HOMEOSTASIS+0.400
- MITOTIC_SPINDLE+0.400
- MYC_TARGETS_V1+0.400
- DNA_REPAIR+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
- HEME_METABOLISM+0.200
- PEROXISOME+0.200
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- COAGULATION-0.400
- HEDGEHOG_SIGNALING-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MYOGENESIS-0.400
- ALLOGRAFT_REJECTION-0.300
- APICAL_JUNCTION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.891 |
| 2 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.889 |
| 3 | SRR1313140 | — | E | 0.888 |
| 4 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.886 |
| 5 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.883 |
| 6 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.883 |
| 7 | 57ab4aef-e740-4494-b0b5-3b008f9d446f | — | — | 0.883 |
| 8 | MNG964 | — | — | 0.881 |
| 9 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.880 |
| 10 | 96a00cc6-3880-4f03-a08d-73d284787971 | — | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |